Eli Lilly Future Growth
Future criteria checks 5/6
Eli Lilly is forecast to grow earnings and revenue by 27.1% and 15.9% per annum respectively. EPS is expected to grow by 27.1% per annum. Return on equity is forecast to be 70.7% in 3 years.
Key information
27.1%
Earnings growth rate
27.1%
EPS growth rate
| Pharmaceuticals earnings growth | 21.0% |
| Revenue growth rate | 15.9% |
| Future return on equity | 70.7% |
| Analyst coverage | Good |
| Last updated | 17 Apr 2024 |
Recent future growth updates
Recent updates
Wall Street Lunch: Lilly In Limelight
Apr 17Eli Lilly: Diabetes And Weight Management Treatments Are The Winning Tickets
Mar 29Eli Lilly: The Party Is Not Over
Mar 23Estimating The Intrinsic Value Of Eli Lilly and Company (NYSE:LLY)
Mar 17
Eli Lilly: Yes, It Is Too Late To Join The Party
Feb 20Eli Lilly: Overvaluation Is A Big Red Flag
Feb 14Eli Lilly and Company: Even 'Miracle Drugs' Can't Keep Stock Rising (Downgrade)
Feb 07Eli Lilly: GLP-1's Potential In More Indications Should Unlock Significant Value
Jan 31Eli Lilly (NYSE:LLY) Has Announced That It Will Be Increasing Its Dividend To $1.30
Jan 24Eli Lilly: The Cupboard Is Fully Stocked
Jan 19Eli Lilly: The Buzz Is Not Over
Jan 11Eli Lilly (NYSE:LLY) Is Increasing Its Dividend To $1.30
Jan 10Eli Lilly (NYSE:LLY) Is Paying Out A Larger Dividend Than Last Year
Dec 27Pinning Down Eli Lilly and Company's (NYSE:LLY) P/S Is Difficult Right Now
Dec 24Eli Lilly: Long Path To A Trillion
Dec 21Eli Lilly (NYSE:LLY) Has A Pretty Healthy Balance Sheet
Dec 05Bubble Warning: Unrealistic Growth Priced In And Multiple Risk Factors For Eli Lilly
Nov 30Eli Lilly: Perfectly Priced Healthcare Giant
Nov 16Eli Lilly: Zepbound For Weight Loss FDA Approved - Time To Believe The Hype?
Nov 09Calculating The Intrinsic Value Of Eli Lilly and Company (NYSE:LLY)
Oct 30Eli Lilly: The GLP-1 Opportunity, While Increasingly Recognized, Is Vastly Underestimated
Oct 11Eli Lilly: Big Cancer Bet With Point Biopharma Global Purchase
Oct 05Eli Lilly: Don't Be Fooled By Greed
Sep 20Eli Lilly Stock Hits New All-Time Highs: Is It Still A Buy?
Sep 11Here's Why We Think Eli Lilly (NYSE:LLY) Is Well Worth Watching
Sep 11Is Eli Lilly (NYSE:LLY) Using Too Much Debt?
Aug 24Sell Eli Lilly And Buy This Coiled-Spring Dividend Aristocrat Instead
Aug 23Eli Lilly Q2: Dividends Don't Lie
Aug 14Eli Lilly Remains A Buy With Strong Sales And Possible Upside With Mounjaro
Aug 08Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 60,671 | 20,615 | 17,469 | 18,197 | 23 |
| 12/31/2025 | 51,354 | 15,824 | 13,259 | 15,009 | 27 |
| 12/31/2024 | 41,359 | 10,922 | 8,386 | 11,125 | 27 |
| 12/31/2023 | 34,124 | 5,240 | -1,548 | 4,240 | N/A |
| 9/30/2023 | 32,073 | 4,988 | 1,374 | 5,713 | N/A |
| 6/30/2023 | 29,516 | 6,498 | 3,211 | 5,741 | N/A |
| 3/31/2023 | 27,691 | 5,687 | 3,786 | 6,292 | N/A |
| 12/31/2022 | 28,541 | 6,245 | 4,696 | 7,586 | N/A |
| 9/30/2022 | 29,240 | 6,033 | 5,404 | 8,080 | N/A |
| 6/30/2022 | 29,071 | 5,692 | 4,950 | 7,494 | N/A |
| 3/31/2022 | 29,323 | 6,129 | 5,824 | 8,086 | N/A |
| 12/31/2021 | 28,318 | 5,582 | 5,604 | 7,366 | N/A |
| 9/30/2021 | 27,759 | 5,972 | 4,621 | 6,919 | N/A |
| 6/30/2021 | 26,726 | 6,071 | 4,837 | 7,095 | N/A |
| 3/31/2021 | 25,486 | 6,093 | 5,565 | 7,815 | N/A |
| 12/31/2020 | 24,540 | 6,194 | 4,471 | 6,500 | N/A |
| 9/30/2020 | 23,214 | 5,573 | 5,112 | 6,648 | N/A |
| 6/30/2020 | 22,950 | 5,618 | 4,890 | 6,352 | N/A |
| 3/31/2020 | 23,087 | 5,533 | 3,684 | 4,908 | N/A |
| 12/31/2019 | 22,320 | 4,638 | 3,483 | 4,837 | N/A |
| 9/30/2019 | 21,843 | 4,264 | 2,671 | 4,322 | N/A |
| 6/30/2019 | 21,673 | 4,103 | 3,324 | 4,933 | N/A |
| 3/31/2019 | 21,622 | 2,545 | 2,217 | 5,399 | N/A |
| 12/31/2018 | 21,493 | 3,151 | 2,506 | 5,525 | N/A |
| 9/30/2018 | 22,016 | 372 | 2,100 | 5,819 | N/A |
| 6/30/2018 | 22,368 | -166 | 1,711 | 5,579 | N/A |
| 3/31/2018 | 22,607 | 1,074 | 3,481 | 5,712 | N/A |
| 12/31/2017 | 19,974 | -86 | 3,452 | 5,616 | N/A |
| 9/30/2017 | 22,471 | 2,225 | N/A | 5,879 | N/A |
| 6/30/2017 | 22,005 | 2,447 | N/A | 5,659 | N/A |
| 3/31/2017 | 21,585 | 2,187 | N/A | 5,410 | N/A |
| 12/31/2016 | 21,222 | 2,738 | N/A | 4,851 | N/A |
| 9/30/2016 | 20,837 | 2,444 | N/A | 3,841 | N/A |
| 6/30/2016 | 20,605 | 2,466 | N/A | 3,284 | N/A |
| 3/31/2016 | 20,179 | 2,319 | N/A | 2,830 | N/A |
| 12/31/2015 | 19,959 | 2,408 | N/A | 2,965 | N/A |
| 9/30/2015 | 19,704 | 2,359 | N/A | 3,318 | N/A |
| 6/30/2015 | 19,620 | 2,059 | N/A | 3,905 | N/A |
| 3/31/2015 | 19,577 | 2,192 | N/A | 4,010 | N/A |
| 12/31/2014 | 19,616 | 2,391 | N/A | 4,458 | N/A |
| 9/30/2014 | 20,303 | 2,690 | N/A | 4,744 | N/A |
| 6/30/2014 | 21,200 | 3,392 | N/A | 5,045 | N/A |
| 3/31/2014 | 22,194 | 3,865 | N/A | 5,628 | N/A |
| 12/31/2013 | 23,113 | 4,685 | N/A | 5,735 | N/A |
| 9/30/2013 | 23,262 | 4,785 | N/A | 5,610 | N/A |
| 6/30/2013 | 22,932 | 4,908 | N/A | 5,163 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: LLY's forecast earnings growth (27.1% per year) is above the savings rate (2.3%).
Earnings vs Market: LLY's earnings (27.1% per year) are forecast to grow faster than the US market (14.6% per year).
High Growth Earnings: LLY's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: LLY's revenue (15.9% per year) is forecast to grow faster than the US market (8.1% per year).
High Growth Revenue: LLY's revenue (15.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: LLY's Return on Equity is forecast to be very high in 3 years time (70.7%).